677 related articles for article (PubMed ID: 16454834)
21. Experimental HBsAg/anti-HBs complex assay for prediction of HBeAg loss in chronic hepatitis B patients treated with pegylated interferon and adefovir.
de Niet A; Jansen L; Zaaijer HL; Klause U; Takkenberg B; Janssen HL; Chu T; Petric R; Reesink HW
Antivir Ther; 2014; 19(3):259-67. PubMed ID: 24256626
[TBL] [Abstract][Full Text] [Related]
22. Natural Killer Cell Characteristics in Patients With Chronic Hepatitis B Virus (HBV) Infection Are Associated With HBV Surface Antigen Clearance After Combination Treatment With Pegylated Interferon Alfa-2a and Adefovir.
Stelma F; de Niet A; Tempelmans Plat-Sinnige MJ; Jansen L; Takkenberg RB; Reesink HW; Kootstra NA; van Leeuwen EM
J Infect Dis; 2015 Oct; 212(7):1042-51. PubMed ID: 25791117
[TBL] [Abstract][Full Text] [Related]
23. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients.
Ma H; Yang RF; Wei L
J Gastroenterol Hepatol; 2010 Sep; 25(9):1498-506. PubMed ID: 20796146
[TBL] [Abstract][Full Text] [Related]
24. Clinical Analysis of Polyethylene Glycol Interferon-α Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients.
Luo X; Yu JX; Xie L; Ma WJ; Wang LH
Ann Hepatol; 2017 November-December,; 16(6):888-892. PubMed ID: 29055925
[TBL] [Abstract][Full Text] [Related]
25. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.
Wong VW; Wong GL; Yan KK; Chim AM; Chan HY; Tse CH; Choi PC; Chan AW; Sung JJ; Chan HL
Hepatology; 2010 Jun; 51(6):1945-53. PubMed ID: 20209602
[TBL] [Abstract][Full Text] [Related]
26. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.
Buster EH; Hansen BE; Lau GK; Piratvisuth T; Zeuzem S; Steyerberg EW; Janssen HL
Gastroenterology; 2009 Dec; 137(6):2002-9. PubMed ID: 19737568
[TBL] [Abstract][Full Text] [Related]
27. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
He LT; Ye XG; Zhou XY
World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
[TBL] [Abstract][Full Text] [Related]
28. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N;
N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917
[TBL] [Abstract][Full Text] [Related]
29. [HBsAg loss with Pegylated-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)-ide analog: new switch study].
Hu P; Shang J; Zhang WH; Gong GZ; Li YG; Chen XY; Jiang JN; Xie Q; Dou XG; Sun YT; Li YF; Liu YX; Liu GZ; Ma DW; Chi XL; Tang H; Li XO; Xie Y; Chen XP; Jiang JJ; Zha P; Hou JL; Gao ZL; Fan HM; Ding JG; Zhang DZ; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2018 Oct; 26(10):756-764. PubMed ID: 30481882
[No Abstract] [Full Text] [Related]
30. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients.
Idilman R; Cinar K; Seven G; Bozkus Y; Elhan A; Bozdayi M; Yurdaydin C; Bahar K
J Viral Hepat; 2012 Mar; 19(3):220-6. PubMed ID: 22329377
[TBL] [Abstract][Full Text] [Related]
31. [Study on the relationship between hepatitis B virus genotypes and the effect of polyethylene glycol-interferon-alpha therapy on HBeAg-positive chronic hepatitis B].
Gao GS; Xu XZ; Hu YR; Yan HD
Zhonghua Nei Ke Za Zhi; 2013 Dec; 52(12):1009-12. PubMed ID: 24503396
[TBL] [Abstract][Full Text] [Related]
32. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels.
Sonneveld MJ; Hansen BE; Piratvisuth T; Jia JD; Zeuzem S; Gane E; Liaw YF; Xie Q; Heathcote EJ; Chan HL; Janssen HL
Hepatology; 2013 Sep; 58(3):872-80. PubMed ID: 23553752
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.
Brunetto MR; Moriconi F; Bonino F; Lau GK; Farci P; Yurdaydin C; Piratvisuth T; Luo K; Wang Y; Hadziyannis S; Wolf E; McCloud P; Batrla R; Marcellin P
Hepatology; 2009 Apr; 49(4):1141-50. PubMed ID: 19338056
[TBL] [Abstract][Full Text] [Related]
34. The effect of pegylated interferon-alpha on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection.
Leemans WF; Flink HJ; Janssen HL; Niesters HG; Schalm SW; de Man RA
J Hepatol; 2006 Mar; 44(3):507-11. PubMed ID: 16457904
[TBL] [Abstract][Full Text] [Related]
35. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B.
Sonneveld MJ; Wong VW; Woltman AM; Wong GL; Cakaloglu Y; Zeuzem S; Buster EH; Uitterlinden AG; Hansen BE; Chan HL; Janssen HL
Gastroenterology; 2012 Mar; 142(3):513-520.e1. PubMed ID: 22108195
[TBL] [Abstract][Full Text] [Related]
36. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy.
Tseng TC; Yu ML; Liu CJ; Lin CL; Huang YW; Hsu CS; Liu CH; Kuo SF; Pan CJ; Yang SS; Su CW; Chen PJ; Chen DS; Kao JH
Antivir Ther; 2011; 16(5):629-37. PubMed ID: 21817184
[TBL] [Abstract][Full Text] [Related]
37. Pegylated interferon results in higher serological, but not virological, response rates when compared to continuous entecavir.
Sonneveld MJ; Zoutendijk R; Hansen BE; Janssen HL
Antivir Ther; 2012; 17(8):1605-8. PubMed ID: 22898565
[TBL] [Abstract][Full Text] [Related]
38. [Effect of interferon-alpha treatment in children with hepatitis B e antigen-positive chronic hepatitis B virus infection: a meta-analysis of follow-up for six months to two years].
Lin ZQ; Fang F; Guo ZF; Chen Q
Zhonghua Er Ke Za Zhi; 2007 Aug; 45(8):592-8. PubMed ID: 18021533
[TBL] [Abstract][Full Text] [Related]
39. [Clinical effect and safety of pegylated interferon-α-2b injection (Y shape, 40 kD) in treatment of HBeAg-positive chronic hepatitis B patients].
Hou FQ; Yin YL; Zeng LY; Shang J; Gong GZ; Pan C; Zhang MX; Yin CB; Xie Q; Peng YZ; Chen SJ; Mao Q; Chen YP; Mao QG; Zhang DZ; Han T; Wang MR; Zhao W; Liu JJ; Han Y; Zhao LF; Luo GH; Zhang JM; Peng J; Tan DM; Li ZW; Tang H; Wang H; Zhang YX; Li J; Zhang LL; Chen L; Jia JD; Chen CW; Zhen Z; Li BS; Niu JQ; Meng QH; Yuan H; Sun YT; Li SC; Sheng JF; Cheng J; Sun L; Wang GQ
Zhonghua Gan Zang Bing Za Zhi; 2017 Aug; 25(8):589-596. PubMed ID: 29056008
[No Abstract] [Full Text] [Related]
40. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis B patients.
Dogan UB; Golge N; Akin MS
Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1312-6. PubMed ID: 23652913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]